Uveal Melanoma with Thickness between 4 and 6 mm Treated with two Different Radioisotopes (I125 or Ru106): Single Institution Experience
Luca TAGLIAFERRI1,Monica Maria PAGLIARA2,Bruno FIONDA1,Andrea SCUPOLA2,Luca BOLDRINI3,Carmela Grazia CAPUTO2,Valentina LANCELLOTTA1,Cesare MARINO4,Giulia MIDENA5,Luigi AZARIO6,Jacopo LENKOWICZ4,Maria Antonietta GAMBACORTA3,Vincenzo VALENTINI3,Maria Antonietta BLASI7
1Fondazione Policlinico Universitario
2Fondazione Policlinico Universitario
3Fondazione Policlinico Universitario
4Università Cattolica del Sacro Cuore, Istituto di Radiologia, Rome-Italy
5Università Cattolica del Sacro Cuore, Istituto di Oftalmologia, Rome-Italy
6Fondazione Policlinico Universitario
7Fondazione Policlinico Universitario
DOI : 10.5505/tjo.2020.2175 OBJECTIVE
This study aims to evaluate if a disease thickness cut-off of 5 mm can be considered the best choice to select gamma emitter sources, as 125I, for the treatment of uveal melanomas.

The records of patients affected by primary uveal melanoma and treated in our institutional IOC (Interventional Oncology Center) from December 2006 to December 2016 were retrospectively reviewed. Only patients with a disease thickness between 4 mm and 6 mm treated with 106Ru or 125I plaque were considered for this analysis.

Between December 2006 and December 2016, 107 patients (107 eyes) with UM received brachytherapy treatment with tumor thickness between 4 and 6 mm. Nine patients developed local recurrence while seven patients had distant metastases. No statistically significant difference (p=0.36) was observed between the two groups (125I versus 106Ru) concerning DFS. Five patients treated with 125I (19.2%) experienced radiation maculopathy; this finding is noteworthy because this toxicity was experienced by 21 patients treated with 106Ru (25.9%).

In this study, we report that the use of 125I seeds for UM with a thickness between 5 mm and 6 mm is not associated with a statistically significant increased risk of radiation maculopathy. It is desirable that further multicentric investigations may help to confirm the results of our study. Keywords : Brachytherapy; interventional radiotherapy; ocular oncology; uveal melanoma